Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in early active axial spondyloarthritis
NCT00844805Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2009
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of infliximab in axial spondyloarthritis (axSpA) (4 arms), sponsored by Merck & Co. Primary endpoint: Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at 28 weeks. Started Sep 2009; status: completed.
02
Drugs
infliximab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT00844805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00844805.